Rankings
▼
Calendar
SUPN FY 2020 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
SUPN
Supernus Pharmaceuticals, Inc.
$3B
FY 2020 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$520M
+32.5% YoY
Gross Profit
$468M
89.9% margin
Operating Income
$174M
33.4% margin
Net Income
$127M
24.4% margin
EPS (Diluted)
$2.36
Cash Flow
Operating Cash Flow
$138M
Free Cash Flow
$135M
Stock-Based Comp.
$17M
Balance Sheet
Total Assets
$1.5B
Total Liabilities
$759M
Stockholders' Equity
$745M
Cash & Equivalents
$289M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$520M
$393M
+32.5%
Gross Profit
$468M
$376M
+24.4%
Operating Income
$174M
$149M
+16.9%
Net Income
$127M
$113M
+12.3%
← Q4 2019
All Quarters
Q1 2020 →